Macular pigment density at the site of altered fundus autofluorescence

Simon Paul Rothenbuehler, Ute E K Wolf-Schnurrbusch, Sebastian Wolf, Simon Paul Rothenbuehler, Ute E K Wolf-Schnurrbusch, Sebastian Wolf

Abstract

Background: The purpose of our study was to determine whether abnormalities of increased or decreased fundus autofluorescence (FAF) are associated with local changes in macular pigment (MP) optical density in patients with age-related maculopathy (ARM) and macular degeneration (ARMD).

Methods: FAF imaging and MP measurement was performed through dilated pupils using a modified confocal scanning laser ophthalmoscope (HRA, Heidelberg Engineering, Germany) according to a standard protocol. Two-wavelength autofluorescence method was employed for determination of local macular pigment optical density (LMPOD). Image analysis and measurement of LMPOD at the area of altered FAF was performed using Heidelberg Eye Explorer Software. Mean values of LMPOD at the site of FAF abnormality were compared to an adjacent location with normal background FAF of the same image.

Results: Sixty-three eyes of 63 patients (28 male, 35 female, mean age 75.8 ± 8.8 years) were included in this analysis. Group 1 comprised 31 cases with focal increased FAF. Mean LMPOD in the area of increased FAF was 0.073 ± 0.083 compared to 0.075 ± 0.074 in the adjacent area of normal FAF. Group 2 comprised 32 cases of focal decreased FAF. Mean LMPOD in the area of decreased FAF was -0.004 ± 0.088 compared 0.053 ± 0.075 in the adjacent area of normal FAF. The site of increased FAF showed no significant difference in LMPOD (p = 0.927) compared to adjacent areas of normal FAF, while areas of decreased FAF revealed significantly lower LMPOD (p = 0.001) compared to adjacent areas of normal FAF.

Conclusions: Focal increases of FAF due to ARM or ARMD did not lead to change in LMPOD. Presumably, retinal layers containing MP are unaffected by these processes. For lesions exhibiting focal decreased FAF, a reduction of LMPOD cannot be excluded. Further studies are needed to investigate MP in the course of disease.

Trial registration: ClinicalTrials.gov NCT00494325.

References

    1. Invest Ophthalmol Vis Sci. 1997 Feb;38(2):478-86
    1. Ophthalmology. 2009 Dec;116(12):2422-9
    1. Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2303-8
    1. Surv Ophthalmol. 2009 Jan-Feb;54(1):96-117
    1. Retina. 2008 Jun;28(6):808-16
    1. Invest Ophthalmol Vis Sci. 1995 Mar;36(3):718-29
    1. Exp Eye Res. 2009 Jun 15;89(1):25-31
    1. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3309-14
    1. Invest Ophthalmol Vis Sci. 2000 Feb;41(2):496-504
    1. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):3940-50
    1. Ophthalmology. 2010 May;117(5):966-71
    1. Ophthalmology. 2007 Feb;114(2):253-62
    1. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4351-7
    1. Invest Ophthalmol Vis Sci. 1984 Jun;25(6):674-85
    1. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):843-5
    1. Arch Ophthalmol. 1998 May;116(5):653-8
    1. Optometry. 2007 May;78(5):213-9
    1. Graefes Arch Clin Exp Ophthalmol. 1999 Feb;237(2):145-52
    1. Graefes Arch Clin Exp Ophthalmol. 2003 Aug;241(8):647-51
    1. Exp Eye Res. 1997 Feb;64(2):211-8
    1. Graefes Arch Clin Exp Ophthalmol. 2005 Apr;243(4):300-5
    1. Am J Ophthalmol. 2007 Mar;143(3):463-72
    1. Graefes Arch Clin Exp Ophthalmol. 2002 Aug;240(8):666-71
    1. Exp Eye Res. 2007 Apr;84(4):718-28
    1. Biofactors. 2000;11(1-2):3-6
    1. J Opt Soc Am A Opt Image Sci Vis. 2001 Jun;18(6):1212-30
    1. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):737-43
    1. Br J Ophthalmol. 1996 Jan;80(1):2-3
    1. Eye (Lond). 2008 Jan;22(1):132-7
    1. Eye (Lond). 2001 Jun;15(Pt 3):384-9
    1. Retina. 2005 Jul-Aug;25(5 Suppl):1519-35
    1. Am J Clin Nutr. 2006 Nov;84(5):1107-22
    1. Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1855-66
    1. Surv Ophthalmol. 2003 May-Jun;48(3):257-93

Source: PubMed

3
Prenumerera